Dataset Information

Ledzewicz2013 - On optimal chemotherapy with a strongly targeted agent for a model of tumor immune system interactions with generalized logistic growth

ABSTRACT: On optimal chemotherapy with a strongly targeted agent for a model of tumor-immune system interactions with generalized logistic growth. Ledzewicz U1, Olumoye O, Schättler H. 1 Dept. of Mathematics and Statistics, Southern Illinois University Edwardsville, Edwardsville, Illinois 62026-1653, USA. uledzew@siue.edu Abstract In this paper, a mathematical model for chemotherapy that takes tumor immune-system interactions into account is considered for a strongly targeted agent. We use a classical model originally formulated by Stepanova, but replace exponential tumor growth with a generalised logistic growth model function depending on a parameter v. This growth function interpolates between a Gompertzian model (in the limit v → 0) and an exponential model (in the limit v → ∞). The dynamics is multi-stable and equilibria and their stability will be investigated depending on the parameter v. Except for small values of v, the system has both an asymptotically stable microscopic (benign) equilibrium point and an asymptotically stable macroscopic (malignant) equilibrium point. The corresponding regions of attraction are separated by the stable manifold of a saddle. The optimal control problem of moving an initial condition that lies in the malignant region into the benign region is formulated and the structure of optimal singular controls is determined

SUBMITTER: Mohammad Umer Sharif Shohan

PROVIDER: BIOMD0000000919 | BioModels | 2024-09-02

REPOSITORIES: BioModels

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	BIOMD0000000919?filename=Ledzewicz2013-biopax2.owl	Owl
	BIOMD0000000919?filename=Ledzewicz2013-biopax3.owl	Owl
	BIOMD0000000919?filename=Ledzewicz2013.cps	Other
	BIOMD0000000919?filename=Ledzewicz2013.sedml	Other
	BIOMD0000000919?filename=Ledzewicz2013.xml	Xml

Items per page:

1 - 5 of 9

Publications

On optimal chemotherapy with a strongly targeted agent for a model of tumor-immune system interactions with generalized logistic growth.

Ledzewicz Urszula U Olumoye Omeiza O Schättler Heinz H

Mathematical biosciences and engineering : MBE 20130601 3

In this paper, a mathematical model for chemotherapy that takes tumor immune-system interactions into account is considered for a strongly targeted agent. We use a classical model originally formulated by Stepanova, but replace exponential tumor growth with a generalised logistic growth model function depending on a parameter v. This growth function interpolates between a Gompertzian model (in the limit v → 0) and an exponential model (in the limit v → ∞). The dynamics is multi-stable and equili ...[more]

PMID: 23906150

Similar Datasets

Project description:Murphy2016 - Differences in predictions of ODE models of tumor growth Comparison of 7 ODE models for tumour size. This models have been compared to experimental data. This model is described in the article: Differences in predictions of ODE models of tumor growth: a cautionary example. Murphy H, Jaafari H, Dobrovolny HM. BMC Cancer 2016 Feb; 16: 163 Abstract: While mathematical models are often used to predict progression of cancer and treatment outcomes, there is still uncertainty over how to best model tumor growth. Seven ordinary differential equation (ODE) models of tumor growth (exponential, Mendelsohn, logistic, linear, surface, Gompertz, and Bertalanffy) have been proposed, but there is no clear guidance on how to choose the most appropriate model for a particular cancer.We examined all seven of the previously proposed ODE models in the presence and absence of chemotherapy. We derived equations for the maximum tumor size, doubling time, and the minimum amount of chemotherapy needed to suppress the tumor and used a sample data set to compare how these quantities differ based on choice of growth model.We find that there is a 12-fold difference in predicting doubling times and a 6-fold difference in the predicted amount of chemotherapy needed for suppression depending on which growth model was used.Our results highlight the need for careful consideration of model assumptions when developing mathematical models for use in cancer treatment planning. This model is hosted on BioModels Database and identified by: BIOMD0000000671. To cite BioModels Database, please use: Chelliah V et al. BioModels: ten-year anniversary. Nucl. Acids Res. 2015, 43(Database issue):D542-8. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Project description:Ribba2012 - Low-grade gliomas, tumour growth inhibition model Using longitudinal mean tumour diameter (MTD) data, this model describe the size evolution of low-grade glioma (LGG) in patients treated with chemotherapy or radiotherapy. This model is described in the article: A tumour growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F. Clin. Cancer Res. 2012 Sep; 18(18): 5071-5080 Abstract: PURPOSE: To develop a tumor growth inhibition model for adult diffuse low-grade gliomas (LGG) able to describe tumor size evolution in patients treated with chemotherapy or radiotherapy. EXPERIMENTAL DESIGN: Using longitudinal mean tumor diameter (MTD) data from 21 patients treated with first-line procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) chemotherapy, we formulated a model consisting of a system of differential equations, incorporating tumor-specific and treatment-related parameters that reflect the response of proliferative and quiescent tumor tissue to treatment. The model was then applied to the analysis of longitudinal tumor size data in 24 patients treated with first-line temozolomide (TMZ) chemotherapy and in 25 patients treated with first-line radiotherapy. RESULTS: The model successfully described the MTD dynamics of LGG before, during, and after PCV chemotherapy. Using the same model structure, we were also able to successfully describe the MTD dynamics in LGG patients treated with TMZ chemotherapy or radiotherapy. Tumor-specific parameters were found to be consistent across the three treatment modalities. The model is robust to sensitivity analysis, and preliminary results suggest that it can predict treatment response on the basis of pretreatment tumor size data. CONCLUSIONS: Using MTD data, we propose a tumor growth inhibition model able to describe LGG tumor size evolution in patients treated with chemotherapy or radiotherapy. In the future, this model might be used to predict treatment efficacy in LGG patients and could constitute a rational tool to conceive more effective chemotherapy schedules. This model is hosted on BioModels Database and identified by: BIOMD0000000521 . To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.